📋 Tender Overview
Contract awarded for Liek with the active substance cerliponase alfa 150 mg, infusion solution lot-0001, title: drug with the active substance cerliponase alfa 150 mg, infusion solution, description: the subject of the contract is a drug with the active substance cerliponase alfa 150 mg, infusion solution. dosage form: solution for infusion 5 ml/150 mg + 5 ml diluent (drug injection vial). administration: intracerebroventricular use. the active substance cerliponase alfa belongs to a group of drugs known as enzyme replacement therapies. it is used to treat patients with neuronal ceroid lipofuscinosis type 2 (cln2), also known as deficiency of tripeptidyl peptidase 1 (tpp1). people with cln2 disease do not have an enzyme called tpp1 or have too little of it, which causes the accumulation of substances known as lysosomal storage materials. in people with cln2 disease, these substances accumulate in certain parts of the body, especially in the brain. this drug replaces the missing enzyme called tppa, thereby minimizing the accumulation of lysosomal storage materials. this drug works by slowing the progression of the disease. the recommended dose is 300 mg of cerliponase alfa, administered once every two weeks by intracerebroventricular infusion. estimated value excluding vat: 2678664.60 eur.Liek with the active substance cerliponase alfa 150 mg, infusion solution